Speciality
Spotlight

       




 


Medicine


   

 




Insulin

    

  • G.B.
    Bolli, David R Owens (Department of Internal
    Medicine, University of Perugia, Italy; Diabetic
    Research Unit, University of Wales College of
    Medicine, UK)

    Commentary
    – Insulin Glargine

    Lancet,
    vol.356, August 5, 2000, p.443-444

      

    Insulin
    glargine is a new long-acting insulin analogue,
    approved for use  in patients with type
    I and Type II diabetes mellitus.
    It is approved by US-FDA and also in Europe.

      

    It
    is produced by recombinant DNA technology.
    It is a clear solution but when injected
    subcutaneously, it forms a microprecipitate at the
    physiological pH of subcutaneous space.
    Absorption is delayed and lasts a long time
    thus providing a fairly constant basal insulin
    supply – similar to basal insulin secretion in
    non-diabetic people in post-absorptive state.

      

    Insulin
    requiring diabetic patients need a new long-acting
    insulin, because NPH, lente and ultralente cannot
    mimic the effect of basal insulin. All existing long-acting insulin preparations have a peak action
    profile, and large within and between subject
    variability in subcutaenous absorption.
    Glucose homeostasis in the interprandial and
    nocturnal periods is finely regulated by slow
    continuous insulin secretion.

      

    Thus,
    an insulin with a peakless action profile should
    improve blood glucose control in Type I diabetic
    patients, especially in those with absolute failure
    of the pancreatic beta-cells.

          

 



 

           

Speciality Spotlight

       

 
Medicine
   

 

Insulin
    

  • G.B. Bolli, David R Owens (Department of Internal Medicine, University of Perugia, Italy; Diabetic Research Unit, University of Wales College of Medicine, UK)
    Commentary – Insulin Glargine
    Lancet, vol.356, August 5, 2000, p.443-444
      
    Insulin glargine is a new long-acting insulin analogue, approved for use  in patients with type I and Type II diabetes mellitus. It is approved by US-FDA and also in Europe.
      
    It is produced by recombinant DNA technology. It is a clear solution but when injected subcutaneously, it forms a microprecipitate at the physiological pH of subcutaneous space. Absorption is delayed and lasts a long time thus providing a fairly constant basal insulin supply – similar to basal insulin secretion in non-diabetic people in post-absorptive state.
      
    Insulin requiring diabetic patients need a new long-acting insulin, because NPH, lente and ultralente cannot mimic the effect of basal insulin. All existing long-acting insulin preparations have a peak action profile, and large within and between subject variability in subcutaenous absorption. Glucose homeostasis in the interprandial and nocturnal periods is finely regulated by slow continuous insulin secretion.
      
    Thus, an insulin with a peakless action profile should improve blood glucose control in Type I diabetic patients, especially in those with absolute failure of the pancreatic beta-cells.
          

 

 

By |2022-07-20T16:42:02+00:00July 20, 2022|Uncategorized|Comments Off on Insulin

About the Author: